# CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma

> **NCT06182735** · PHASE1 · UNKNOWN · sponsor: **Fudan University** · enrollment: 9 (estimated)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **COMBINATION_PRODUCT:** Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells

## Key facts

- **NCT ID:** NCT06182735
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-17
- **Primary completion:** 2025-01-28
- **Final completion:** 2025-01-28
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2023-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06182735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06182735, "CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06182735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*